BCL2 and type 1 diabetes mellitus: Although clinical evaluations of this therapeutic concept and efficacy of ABT199 in T1DM should be investigated further, this suggested that transient elimination of senescent or high Bcl-2-expressing cells may halt insulitis and preserve non-senescent islets, which lead to prevention or delay of T1DM onset.